COGNOSCI INC

Basic Information

2 DAVIS DR
RESEARCH TRIANGLE PARK, NC, 27709-0000

Company Profile

n/a

Additional Details

Field Value
DUNS: 141881727
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: 4


  1. Antagonizing the SET Oncoprotein

    Amount: $225,000.00

    DESCRIPTION provided by applicant We discovered that the SET oncoprotein is overexpressed in of biopsy samples from patients with hematological cancers and about of biopsy samples from pati ...

    SBIR Phase I 2015 Department of Health and Human Services National Institutes of Health
  2. Novel Orally-Available Prodrugs for Alzheimer's Disease

    Amount: $225,000.00

    DESCRIPTION provided by applicant Alzheimerandapos s Disease AD is a progressive neuro degenerative disease that affects over million aged Americans and their million caregivers While the ...

    SBIR Phase I 2015 Department of Health and Human Services National Institutes of Health
  3. Inhibitor #2 of Protein Phosphatase 2A (I2PP2A) and Asthma

    Amount: $268,220.00

    DESCRIPTION (provided by applicant): Over 24 million Americans suffer from asthma, which has become a chronic inflammatory disease of the airways characterized by reversible airflow obstruction and br ...

    SBIR Phase I 2014 Department of Health and Human Services
  4. Novel Drug VS-105 for Treatment of Osteoporosis

    Amount: $273,242.00

    DESCRIPTION (provided by applicant): Investigational Safety and Toxicity Studies of Subcutaneous COG1410 for Alzheimer's Disease: A Therapeutic Based upon Apolipoprotein-E That is Not Targeted to ...

    SBIR Phase I 2013 Department of Health and Human Services
  5. CDX-301 and Plerixafor Combination in Stem Cell Mobilization for Transplantation

    Amount: $225,067.00

    DESCRIPTION (provided by applicant): Diabetic peripheral neuropathy (DPN) is one of the most common and devastating complications of diabetes mellitus, affecting more than 50% of diabetic patients, an ...

    SBIR Phase I 2013 Department of Health and Human Services
  6. Novel COG Compounds to Treat Asthma

    Amount: $261,824.00

    DESCRIPTION (provided by applicant): Our overall goal is to market a COG compound (aka. apoE-mimetic peptides) for the treatment of patients with asthma. Cognosci has discovered, patented and publish ...

    SBIR Phase I 2012 Department of Health and Human Services
  7. Sustained Release Formulation for Treatment of Autoimmune Disease MS

    Amount: $279,054.00

    DESCRIPTION (provided by applicant): Multiple sclerosis (MS) is an inflammatory autoimmune disease in young adults, affecting more than 530,000 people in the United States and approximately 2 million ...

    SBIR Phase I 2011 Department of Health and Human Services
  8. High Throughput Screen for Novel Anti-Rheumatic Compounds

    Amount: $333,305.00

    DESCRIPTION (provided by applicant): Rheumatoid arthritis (RA) is a chronic, systemic, inflammatory autoimmune disease targeting the synovium, the tissue that lines the joints. It is associated wi ...

    SBIR Phase I 2010 Department of Health and Human Services
  9. Therapeutic for Intracerebral Hemorrhage

    Amount: $258,584.00

    DESCRIPTION (provided by applicant): Intracerebral hemorrhage (ICH) is a devastating and relatively common disease affecting as many as 50,000 people annually in the United States alone. ICH remains ...

    SBIR Phase I 2009 Department of Health and Human Services
  10. Novel Restorative Therapy for Spinal Cord Injury

    Amount: $1,216,440.00

    DESCRIPTION (provided by applicant): Novel Restorative Therapy for Spinal Cord Injury Spinal cord injury (SCI) is a devastating traumatic CNS disorder that significantly disables about 253,000 America ...

    SBIR Phase II 2009 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government